Empagelfosin works by blocking a kidney protein called sodiumglucose cotransporter 2 (SGLT2). SGLT2 prevents loss of glucose in the urine by reverse absorption of glucose into the bloodstream during blood filtration through the kidneys. By blocking this protein, the medicine causes the blood sugar to be released into the urine. This helps to lower blood glucose levels that are elevated in patients with type 2 diabetes;
Metformin works differently to lower blood sugar levels in the blood, mainly by blocking the production of glucose in the liver.
Synjardy is added to diet and exercise to treat type 2 diabetes in adult patients (18 years of age and older) in whom diabetes can not be controlled by the addition of metformin alone or metformin and other diabetes medicines.
Synjardy can also be combined with other medicines. These may be oral medicines or insulin injections.
In addition, Synjardy may be used as an alternative to taking epiglyphosine and metformin as separate tablets. To avoid overdosage, do not continue to take the individual tablets of emfgliflozine and metformin if you are taking this medicine.
It is important to continue with your diet and exercise, as your doctor, pharmacist or nurse has told you.